PrEP
Sudden syphilis retreat in gay men is likely tied to preventive antibiotic use
NBC News, November 12, 2024
A historic retreat in syphilis cases among gay and bisexual men has inspired hope among public health experts, who attributed the sudden turnaround to preventive use of the antibiotic doxycycline in this population. DoxyPEP, as the protocol is known is an apparent sleeper hit.
NBC News, November 12, 2024
A historic retreat in syphilis cases among gay and bisexual men has inspired hope among public health experts, who attributed the sudden turnaround to preventive use of the antibiotic doxycycline in this population. DoxyPEP, as the protocol is known is an apparent sleeper hit.
An injectable HIV-prevention drug is highly effective — but wildly expensive
NBC News, Sept. 12, 2024
The hotly anticipated results are in from a landmark pair of major clinical trials of a long-acting, injectable HIV-prevention drug that only requires dosing every six months. They are sensational. And yet, as battle-worn public health advocates stand on the front lines of an over four-decade effort to finally bring the U.S. HIV epidemic to heel, they find a cold, hard fact staring back at them: Lenacapavir is extraordinarily expensive.
NBC News, Sept. 12, 2024
The hotly anticipated results are in from a landmark pair of major clinical trials of a long-acting, injectable HIV-prevention drug that only requires dosing every six months. They are sensational. And yet, as battle-worn public health advocates stand on the front lines of an over four-decade effort to finally bring the U.S. HIV epidemic to heel, they find a cold, hard fact staring back at them: Lenacapavir is extraordinarily expensive.
Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug
NBC News: June 21, 2024
A federal appeals court found unconstitutional a key component of the Affordable Care Act that grants a health task force the effective authority to require that insurers both cover an array of preventive health interventions and screenings and refrain from imposing out-of-pocket costs for them. If the Supreme Court ultimately overturns this pillar, it could raise related out-of-pocket health care costs.
NBC News: June 21, 2024
A federal appeals court found unconstitutional a key component of the Affordable Care Act that grants a health task force the effective authority to require that insurers both cover an array of preventive health interventions and screenings and refrain from imposing out-of-pocket costs for them. If the Supreme Court ultimately overturns this pillar, it could raise related out-of-pocket health care costs.
A Fading Weapon in the HIV Fight: Condoms
The New York Times, February 27, 2024
Gay and bisexual men are using condoms less than ever, and the decline has been particularly steep among those who are young or Hispanic, according to a new study. The worrisome trend points to an urgent need for better prevention strategies as the nation struggles to beat the H.I.V. epidemic, researchers said. The CDC reports that between 2017 and 2021, the nation saw only an estimated 12 percent decline in HIV transmissions.
The New York Times, February 27, 2024
Gay and bisexual men are using condoms less than ever, and the decline has been particularly steep among those who are young or Hispanic, according to a new study. The worrisome trend points to an urgent need for better prevention strategies as the nation struggles to beat the H.I.V. epidemic, researchers said. The CDC reports that between 2017 and 2021, the nation saw only an estimated 12 percent decline in HIV transmissions.
Will first FDA-approved at-home test for gonorrhea, chlamydia ease the epidemic?
NBC News, November 27, 2023
The Food and Drug Administration’s first-ever approval of an at-home test for chlamydia and gonorrhea could help drive earlier detection and treatment of these sexually transmitted infections amid a ballooning epidemic in the U.S. But some sexual health advocates worry that the FDA’s proposal to begin stepping up regulation of over-the-counter self-testing of STIs could backfire.
NBC News, November 27, 2023
The Food and Drug Administration’s first-ever approval of an at-home test for chlamydia and gonorrhea could help drive earlier detection and treatment of these sexually transmitted infections amid a ballooning epidemic in the U.S. But some sexual health advocates worry that the FDA’s proposal to begin stepping up regulation of over-the-counter self-testing of STIs could backfire.
Insurers must cover injectable HIV prevention drug — unless courts void mandate
NBC News, August 22, 2023
A health task force’s new endorsement of a long-acting injectable medication for use as HIV prevention will require health insurers to begin covering the pricey drug by 2025. However, the hotly anticipated development is on a legal collision course.
NBC News, August 22, 2023
A health task force’s new endorsement of a long-acting injectable medication for use as HIV prevention will require health insurers to begin covering the pricey drug by 2025. However, the hotly anticipated development is on a legal collision course.
FDA policy allowing more gay and bisexual men to donate blood goes into effect
NBC News, August 7, 2023
In a victory for LGBTQ rights, a broad swath of the U.S. population of gay men became newly able donate blood, thanks to the implementation by the American Red Cross of a landmark recent change in Food and Drug Administration policy. The policy newly permits donations from men in monogamous relationships with other men, as well as those who have not recently engaged in anal sex.
NBC News, August 7, 2023
In a victory for LGBTQ rights, a broad swath of the U.S. population of gay men became newly able donate blood, thanks to the implementation by the American Red Cross of a landmark recent change in Food and Drug Administration policy. The policy newly permits donations from men in monogamous relationships with other men, as well as those who have not recently engaged in anal sex.
In remission from HIV, a sixth person could join the club of those possibly cured
NBC News, July 19, 2023
A European man has been in a state of remission from HIV infection for nearly two years after receiving a stem cell transplant to treat blood cancer. If enough time passes with no signs of viable virus, he could join five people who are considered either definitely or possibly cured of HIV. His case is unique because his transplant wasn't from a donor with a rare genetic abnormality generating HIV-resistant immune cells.
NBC News, July 19, 2023
A European man has been in a state of remission from HIV infection for nearly two years after receiving a stem cell transplant to treat blood cancer. If enough time passes with no signs of viable virus, he could join five people who are considered either definitely or possibly cured of HIV. His case is unique because his transplant wasn't from a donor with a rare genetic abnormality generating HIV-resistant immune cells.
U.S. progress in HIV fight continues to trail many other rich nations
NBC News, May 23, 2023
New HIV infections continue to ebb only modestly in the United States, while many other wealthy Western nations have posted steep reductions, thanks to more successful efforts overseas to promptly diagnose and treat the virus and promote the HIV prevention pill, PrEP.
NBC News, May 23, 2023
New HIV infections continue to ebb only modestly in the United States, while many other wealthy Western nations have posted steep reductions, thanks to more successful efforts overseas to promptly diagnose and treat the virus and promote the HIV prevention pill, PrEP.
PrEP's promise to change the course of HIV has succeeded—but only for white gay men
NBC News, March 18, 2023
A decade into the era of the HIV prevention pill, called PrEP, efforts to leverage its heralded power to curb new infections have stagnated in the United States. This shortfall is a key reason the nation lags far behind many others in combating HIV, with a national epidemic long plagued by racial inequities and only a modestly declining new infection rate.
NBC News, March 18, 2023
A decade into the era of the HIV prevention pill, called PrEP, efforts to leverage its heralded power to curb new infections have stagnated in the United States. This shortfall is a key reason the nation lags far behind many others in combating HIV, with a national epidemic long plagued by racial inequities and only a modestly declining new infection rate.
HIV Tennessee axed millions in HIV funds amid scrutiny from far-right provocateurs
NBC News, February 2, 2023
Tennessee’s recent decision to reject over $8 million in federal funds to combat HIV was motivated, at least in part, by right-wing provocateurs stoking anti-LGBTQ sentiment, according to four sources within the state Health Department. The move by Republican Gov. Bill Lee will hamstring, if not cripple, efforts to combat one of the country’s most poorly controlled epidemics of the virus, HIV advocates said.
NBC News, February 2, 2023
Tennessee’s recent decision to reject over $8 million in federal funds to combat HIV was motivated, at least in part, by right-wing provocateurs stoking anti-LGBTQ sentiment, according to four sources within the state Health Department. The move by Republican Gov. Bill Lee will hamstring, if not cripple, efforts to combat one of the country’s most poorly controlled epidemics of the virus, HIV advocates said.
Government can't mandate coverage for drugs that prevent HIV, Texas federal judge rules
NBC News, September 2022
A federal judge in Texas has ruled that a provision of the Affordable Care Act that mandates free coverage of HIV-prevention drugs violates the religious beliefs of a Christian-owned company. The ruling by U.S. District Judge Reed O’Connor came in response to a lawsuit filed by Jonathan Mitchell, a former Texas solicitor general.
NBC News, September 2022
A federal judge in Texas has ruled that a provision of the Affordable Care Act that mandates free coverage of HIV-prevention drugs violates the religious beliefs of a Christian-owned company. The ruling by U.S. District Judge Reed O’Connor came in response to a lawsuit filed by Jonathan Mitchell, a former Texas solicitor general.
Because of Covid, 2020 was a 'lost year' in the fight against HIV, report suggests
NBC News, May 2020
An ambitious new plan by the federal government, marshaled by Dr. Anthony Fauci, to accelerate the battle against the U.S. HIV epidemic appears to have made a markedly disappointing debut. CDC officials have expressed concern that disruptions the country’s Covid-19 response have caused to HIV-related services have inflicted collateral damage that could take years to undo.
NBC News, May 2020
An ambitious new plan by the federal government, marshaled by Dr. Anthony Fauci, to accelerate the battle against the U.S. HIV epidemic appears to have made a markedly disappointing debut. CDC officials have expressed concern that disruptions the country’s Covid-19 response have caused to HIV-related services have inflicted collateral damage that could take years to undo.
New injectable HIV prevention drug fails in seven people
NBC News, February 2022
In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their injections on schedule. The new findings indicate that, just as with those who take daily pills to prevent HIV, breakthrough infections are possible among people receiving Apretude.
NBC News, February 2022
In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their injections on schedule. The new findings indicate that, just as with those who take daily pills to prevent HIV, breakthrough infections are possible among people receiving Apretude.
FDA Approves First Injectable HIV Prevention Drug
NBC News, December 2021
The FDA has approved the first long-acting injectable medication for use as pre-exposure prevention, or PrEP, against HIV. Apretude is an injectable given every two months as an alternative to HIV prevention pills, like Truvada and Descovy, which have been shown to reduce the risk of HIV by 99 percent when taken daily. Two FDA trials analyzing the safety and efficacy of the novel drug found that Apretude was more likely to reduce HIV than the daily oral medications.
NBC News, December 2021
The FDA has approved the first long-acting injectable medication for use as pre-exposure prevention, or PrEP, against HIV. Apretude is an injectable given every two months as an alternative to HIV prevention pills, like Truvada and Descovy, which have been shown to reduce the risk of HIV by 99 percent when taken daily. Two FDA trials analyzing the safety and efficacy of the novel drug found that Apretude was more likely to reduce HIV than the daily oral medications.
Long-acting HIV-prevention drugs may be key to beating the epidemic in the U.S.
NBC News, July 2021
Dosed no more frequently than monthly, these experimental drugs offer potential solutions to a problem that has long frustrated the HIV fight: that many at-risk people find adhering to a daily preventive medication too burdensome. But will a critical mass of Black and Latino gay and bisexual men, who comprise nearly half of new HIV diagnoses, end up taking these drugs?
NBC News, July 2021
Dosed no more frequently than monthly, these experimental drugs offer potential solutions to a problem that has long frustrated the HIV fight: that many at-risk people find adhering to a daily preventive medication too burdensome. But will a critical mass of Black and Latino gay and bisexual men, who comprise nearly half of new HIV diagnoses, end up taking these drugs?
PrEP, the HIV prevention pill, must now be totally free under almost all insurance plans
NBC News, July 2021
In a move hailed as potentially transformative by HIV advocates, the federal government has issued a guidance instructing almost all insurance plans to stop charging all out-of-pocket fees for the HIV prevention pill, known as PrEP. This includes the medication itself and, crucially, the quarterly clinic visits and lab tests required to maintain the prescription.
NBC News, July 2021
In a move hailed as potentially transformative by HIV advocates, the federal government has issued a guidance instructing almost all insurance plans to stop charging all out-of-pocket fees for the HIV prevention pill, known as PrEP. This includes the medication itself and, crucially, the quarterly clinic visits and lab tests required to maintain the prescription.
'This will shut us down': HIV prevention clinics brace for Gilead reimbursement cuts
NBC News, July 2021
HIV prevention clinics are facing a fiscal crisis owing to the vagaries of an arcane federal drug pricing law, with a bare minimum of $100 million annually expected to drain from the nonprofits starting in 2022. This devastating loss of funds, which is expected to shut down some clinics, comes just as the federal government has ramped up spending in an effort to essentially end the HIV epidemic by 2030.
NBC News, July 2021
HIV prevention clinics are facing a fiscal crisis owing to the vagaries of an arcane federal drug pricing law, with a bare minimum of $100 million annually expected to drain from the nonprofits starting in 2022. This devastating loss of funds, which is expected to shut down some clinics, comes just as the federal government has ramped up spending in an effort to essentially end the HIV epidemic by 2030.
HIV After COVID: Anthony Fauci and an Army of Researchers Seek to Regain Momentum
The Guardian, June 2021
HIV was instrumental in training armies within the medical, scientific and public health sectors to better fight COVID-19. However, the new pandemic has apparently worsened its predecessor. This comes during the initial roll-out of the national plan Dr. Anthony Fauci designed to ramp up federal spending on HIV with a goal of ending that virus as a public health threat by 2030.
The Guardian, June 2021
HIV was instrumental in training armies within the medical, scientific and public health sectors to better fight COVID-19. However, the new pandemic has apparently worsened its predecessor. This comes during the initial roll-out of the national plan Dr. Anthony Fauci designed to ramp up federal spending on HIV with a goal of ending that virus as a public health threat by 2030.
Trump Success In Ending Obamacare Would Kill Fauci Plan to Conquer HIV
The Guardian, October 2020
In his State of the Union in February 2019, Donald Trump vowed to end the HIV epidemic by 2030. But if Trump has his way and the Supreme Court strikes down the Affordable Care Act (ACA) the resulting disruption to the healthcare system would end that dream. “The plan is dead in the water if the ACA goes down,” said Nastad's Amy Killelea.
25 Years of HIV Research
POZ, July 2019
To mark POZ magazine's 25th anniversary: a review of the extra-ordinary achievements on the part of HIV scientists since 1994. The ever-refined collective mastery they have gained over the virus during this period represents one of the greatest achievements of human ingenuity.
POZ, July 2019
To mark POZ magazine's 25th anniversary: a review of the extra-ordinary achievements on the part of HIV scientists since 1994. The ever-refined collective mastery they have gained over the virus during this period represents one of the greatest achievements of human ingenuity.
Truvada and the Truth: Is HIV Prevention Propelling the STI Epidemic?
The Guardian, October 2018
Among gay and bisexual men, a rapidly expanding STI epidemic is fueling questions about whether the steadily rising number of people who start Truvada for HIV prevention subsequently change their sexual behavior in ways that increase their risk of contracting chlamydia, gonorrhea, syphilis and, in rarer cases, hepatitis C.
The Guardian, October 2018
Among gay and bisexual men, a rapidly expanding STI epidemic is fueling questions about whether the steadily rising number of people who start Truvada for HIV prevention subsequently change their sexual behavior in ways that increase their risk of contracting chlamydia, gonorrhea, syphilis and, in rarer cases, hepatitis C.
Enough people are taking the HIV-prevention drug to finally lower infection rates in the U.S.
Quartz, June 2018
Six years after the Food and Drug Administration approved a revolutionary HIV prevention pill known as PrEP, public health officials in select U.S. cities have finally begun to conclude that it is likely taking a bite out of local HIV infection rates.
Quartz, June 2018
Six years after the Food and Drug Administration approved a revolutionary HIV prevention pill known as PrEP, public health officials in select U.S. cities have finally begun to conclude that it is likely taking a bite out of local HIV infection rates.
Is Gilead’s Entire HIV Enterprise Built on a False Promise?
POZ, May 2018
Gilead Sciences' updated version of its key HIV drug tenofovir may not actually offer any safety benefits when it isn't paired with a so-called boosting agent. A major study is underway comparing the efficacy as PrEP of Truvada, which contains the old tenofovir and no booster, with Descovy, an equivalent tablet including the updated tenofovir. Will Descovy prove significantly safer or is the study for naught?
POZ, May 2018
Gilead Sciences' updated version of its key HIV drug tenofovir may not actually offer any safety benefits when it isn't paired with a so-called boosting agent. A major study is underway comparing the efficacy as PrEP of Truvada, which contains the old tenofovir and no booster, with Descovy, an equivalent tablet including the updated tenofovir. Will Descovy prove significantly safer or is the study for naught?
Generation PrEP?
POZ, April 2018
By and large, men who have sex with men who use Truavda as pre-exposure prophylaxis (PrEP) against HIV are white and over the age of 25. In light of recent HIV diagnosis trends, the lopsidedness of these PrEP uptake numbers reveals the troubling truth lurking behind all the recent fanfare about the HIV prevention method: It is failing to reach many of those who stand to benefit from it the most.
POZ, April 2018
By and large, men who have sex with men who use Truavda as pre-exposure prophylaxis (PrEP) against HIV are white and over the age of 25. In light of recent HIV diagnosis trends, the lopsidedness of these PrEP uptake numbers reveals the troubling truth lurking behind all the recent fanfare about the HIV prevention method: It is failing to reach many of those who stand to benefit from it the most.
"Unpacking Michael Weinstein's Latest PrEP Denialism."
POZ, October 2017
After something of a lull, AIDS Healthcare Foundation (AHF) president Michael Weinstein has revived his ever-the-skeptic public campaign regarding Truvada as pre-exposure prophylaxis (PrEP), publishing a critical editorial on the HIV prevention method in the prestigious medical journal AIDS.
POZ, October 2017
After something of a lull, AIDS Healthcare Foundation (AHF) president Michael Weinstein has revived his ever-the-skeptic public campaign regarding Truvada as pre-exposure prophylaxis (PrEP), publishing a critical editorial on the HIV prevention method in the prestigious medical journal AIDS.
"International HIV Conference Reveals Exciting Progress in Global HIV Fight"
(POZ, August 2017)
The fight to combat the global HIV epidemic is charting exciting progress. This includes a rapidly increasing proportion of those living with the virus on treatment as well as falling infection and AIDS-related death rates. But considerable challenges remain.
(POZ, August 2017)
The fight to combat the global HIV epidemic is charting exciting progress. This includes a rapidly increasing proportion of those living with the virus on treatment as well as falling infection and AIDS-related death rates. But considerable challenges remain.
"Measuring Success as PrEP Turns Five"
(POZ, July 2017)
The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates. But troubling disparities persist, as PrEP's use remains largely relegated to white men who have sex with men (MSM) age 25 and older. Such a trend may ultimately widen existing racial disparities in HIV rates among MSM.
(POZ, July 2017)
The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates. But troubling disparities persist, as PrEP's use remains largely relegated to white men who have sex with men (MSM) age 25 and older. Such a trend may ultimately widen existing racial disparities in HIV rates among MSM.
"HIV 2020"
(POZ, June 2017)
The dawning of the 2020s will bring HIV into its fifth decade. Crystal balls are by their nature hazy, and the current political climate raises many worrisome questions about how shifting federal priorities may affect people living with and at risk for HIV. Nevertheless, thanks to recent promising strides in HIV research and public health efforts to tackle the virus from all sides, leaders in the field are increasingly optimistic about what the next decade of the epidemic will look like.
(POZ, June 2017)
The dawning of the 2020s will bring HIV into its fifth decade. Crystal balls are by their nature hazy, and the current political climate raises many worrisome questions about how shifting federal priorities may affect people living with and at risk for HIV. Nevertheless, thanks to recent promising strides in HIV research and public health efforts to tackle the virus from all sides, leaders in the field are increasingly optimistic about what the next decade of the epidemic will look like.
"As the U.S. Wrests Greater Control Over HIV, What's the Key to Success?"
(POZ, April 2017)
Things are looking up in the U.S. HIV epidemic, with a likely increasing proportion of those living with HIV on treatment and virally suppressed. Going forward, addressing disparities, especially racial ones, is vital for further progress.
(POZ, April 2017)
Things are looking up in the U.S. HIV epidemic, with a likely increasing proportion of those living with HIV on treatment and virally suppressed. Going forward, addressing disparities, especially racial ones, is vital for further progress.
In March 2017, I was a guest on National Public Radio's 1A program to discuss Truvada as pre-exposure prophylaxis (PrEP) against HIV along with the NIAID's Anthony Fauci, the National Minority AIDS Council's Matthew Rose and author Evan J. Peterson.
"PrEP Fails in a Third Man, but This Time HIV Drug Resistance Is Not to Blame."
(POZ, February 2017)
A Dutch man has contracted a non-drug-resistant strain of HIV while, according to numerous sources of evidence, adhering well to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP). His case has puzzled experts because the only two cases of PrEP failure documented thus far, both reported within the past year, involved rare drug-resistant strains of the virus that apparently evaded the two drugs in Truvada.
(POZ, February 2017)
A Dutch man has contracted a non-drug-resistant strain of HIV while, according to numerous sources of evidence, adhering well to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP). His case has puzzled experts because the only two cases of PrEP failure documented thus far, both reported within the past year, involved rare drug-resistant strains of the virus that apparently evaded the two drugs in Truvada.
"PrEP: A Dream Deferred."
(POZ, January 2017)
Truvada as pre-exposure prophylaxis (PrEP) is failing the demographic that needs it most, black men who have sex with men (MSM). Meanwhile, Truvada’s increasing popularity as HIV prevention among white MSM means PrEP is apparently on a path to widen already tragic racial disparities in infection rates among MSM.
Are those who launched PrEP to blame for failing to anticipate its anemic uptake among black MSM?
(POZ, January 2017)
Truvada as pre-exposure prophylaxis (PrEP) is failing the demographic that needs it most, black men who have sex with men (MSM). Meanwhile, Truvada’s increasing popularity as HIV prevention among white MSM means PrEP is apparently on a path to widen already tragic racial disparities in infection rates among MSM.
Are those who launched PrEP to blame for failing to anticipate its anemic uptake among black MSM?
"A Tale of Two Cities."
(POZ, May 2016)
New York City and San Francisco want to end their HIV epidemics.
San Francisco recently launched a multipronged HIV-fighting campaign called “Getting to Zero,” in which the members of local academia, the public health department and community-based organizations, as well as government officials and health care providers, are working in lockstep. Meanwhile, the major players in New York’s epidemic have formed a similar alliance.
(POZ, May 2016)
New York City and San Francisco want to end their HIV epidemics.
San Francisco recently launched a multipronged HIV-fighting campaign called “Getting to Zero,” in which the members of local academia, the public health department and community-based organizations, as well as government officials and health care providers, are working in lockstep. Meanwhile, the major players in New York’s epidemic have formed a similar alliance.
"PrEP Fails in Gay Man Adhering to Daily Truvada,
He Contracts Drug-Resistant HIV."
(POZ, February 2016)
Researchers have for the first time documented a case of an individual contracting HIV, a multi-drug resistant strain, while apparently adhering well to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP). The scientists concluded that it is indeed possible for individuals who are adherent to PrEP to contract HIV when they are exposed to a virus that is resistant to both drugs included in Truvada. While this case is concerning, experts in the PrEP field suggest that such failures of PrEP will likely remain rare.
He Contracts Drug-Resistant HIV."
(POZ, February 2016)
Researchers have for the first time documented a case of an individual contracting HIV, a multi-drug resistant strain, while apparently adhering well to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP). The scientists concluded that it is indeed possible for individuals who are adherent to PrEP to contract HIV when they are exposed to a virus that is resistant to both drugs included in Truvada. While this case is concerning, experts in the PrEP field suggest that such failures of PrEP will likely remain rare.
"There’s Never Been a Better Time to Get Pregnant If One of You Has HIV."
(POZ, September 2016)
Throughout the decade, scientific research has brought into increasingly sharp focus the awesome power of antiretrovirals (ARVs) to prevent HIV transmission. This is excellent news for those looking to conceive a child when one or both of the prospective parents are living with HIV. Having a baby without transmitting the virus to the parent or the baby can now be as simple as taking a pill every day—without significant medication toxicities.
(POZ, September 2016)
Throughout the decade, scientific research has brought into increasingly sharp focus the awesome power of antiretrovirals (ARVs) to prevent HIV transmission. This is excellent news for those looking to conceive a child when one or both of the prospective parents are living with HIV. Having a baby without transmitting the virus to the parent or the baby can now be as simple as taking a pill every day—without significant medication toxicities.
"Is the U.S. HIV Epidemic in Much Better Shape Than We’ve Thought?"
(POZ, May 2016)
Here’s the good news: There may be considerably fewer people living with HIV in the United States, and the HIV population may have a much higher rate of viral suppression than the Centers for Disease Control and Prevention (CDC) has estimated. The bad news is that the CDC’s potentially faulty estimates may have thrown off various other presumptions about the state of the U.S. HIV epidemic and what efforts are needed to drive down new infections.
(POZ, May 2016)
Here’s the good news: There may be considerably fewer people living with HIV in the United States, and the HIV population may have a much higher rate of viral suppression than the Centers for Disease Control and Prevention (CDC) has estimated. The bad news is that the CDC’s potentially faulty estimates may have thrown off various other presumptions about the state of the U.S. HIV epidemic and what efforts are needed to drive down new infections.
"Gay Men Are Using Condoms Less, But Their Use Varies Based on Context." (POZ, January 2016)
Nearly two-thirds of gay men in a large survey reported condomless anal sex. |
"The State of the Epidemic."
(POZ, January 2016) Following years of apparent stag-nation in the U.S. fight against HIV, recent reports suggest that things are looking up. |
"When Can We Expect PrEP 2.0?" (POZ, December 2015) What does the future hold for new forms of pre-exposure prophylaxis (PrEP) against HIV? |
“Fact-Checking AIDS Healthcare Foundation's Latest Anti-PrEP Screed.” (POZ, July 2015) An audit of AHF's ad attacking PrEP revealed a laundry list of errors, if not flat-out lies—and ultimately prompted a spirited AHF rebuttal.
|
"After 2.5 Years, No One in Large SF PrEP Group Contracts HIV." (POZ, September 2015) Two and a half years into a PrEP program in San Francisco, none of the more than 600 men who have sex with men taking the HIV prevention medication have contracted the virus.
|
“PrEP and Prejudice.” (POZ, Oct. 2014) Can personal choice and public health find common ground in pre-exposure prophylaxis? (Winner of the Excellence in HIV/AIDS coverage Award from the National Lesbian & Gay Journalists Assoc.)
|
Michelangelo Signorile interviewed me for his SiriusXM satellite radio show, The Gist, on Sept. 4, 2015. We spoke about the new scientific paper about PrEP's apparent success in preventing HIV among a large group of men who have sex with men in San Francisco (described above). We also discussed whether PrEP will succeed in reducing HIV incidence in the gay community at large, and touched on the anti-PrEP campaigning of AIDS Healthcare Foundation's Michael Weinstein.
“The Audacity of New York's Hope to End AIDS” (POZ, May 2015) Can the Empire State end its epidemic by the decade's end? And what exactly would it mean to do so?
“100% Efficacy for Gays Who Ad-hered in PrEP Study; Most Didn’t.” (POZ, July 2014) Results from the open-label extension phase of the iPrEx study of Truvada among MSM.
|
“AIDS Conference Bolsters the Use of HIV Meds as Prevention.” (POZ, Aug. 2015) A review of studies pre-sented at the International AIDS Society Conference in Vancouver.
“How Well Do Condoms and PrEP Prevent HIV Among Gay Men?” (POZ, Feb. 2015) It's hard to know when CDC estimates about condom effectiveness come from faulty logic.
|
“PrEP Is Ready for Primetime.” (POZ, March 2015) New research under-scores Truvada's great potential for preventing HIV among gay and bisexual men.
“Thanks for Nothing: iPrEX Volun-teers Shut Out of PrEP’s Success.” (POZ, May 2014) Most foreign par-ticipants in the first PrEP trial no longer have access to the drug.
|
PrEP Archive
(These shorter news items do not have bylines, although I did write all of them.)
(These shorter news items do not have bylines, although I did write all of them.)
- Sept. 2018: "Perhaps 4% of Gay & Bi Men Took PrEP During Year Ending March 2017"
- Sept. 2018: "Gay & Bi Men Study Participants' Reported PrEP Use Has Nearly Doubled Annually"
- POZ, Aug. 2018: "Why Do Some Gay and Bi Men Stigmatize PrEP Users?"
- POZ, Aug. 2018: "Starting PrEP Is Tied to 21% Rise in STI Rate in Gay and Bi Australians"
- POZ, Aug. 2018: "All the AIDS Conference News That’s Fit to Print"
- POZ, July 2018: "Just 15% of Those Who’ve Started PrEP Are Younger Than 25"
- POZ, July 2018: "Time San Franciscans Spend With Transmissible HIV Has Greatly Declined"
- POZ, July 2018: "Rising PrEP Use Is Associated With Declining HIV Diagnoses in United States"
- POZ, July 2018: "Hormone Treatment Tied to Lower Truvada Level in Trans Women on PrEP"
- POZ, July 2018: "No New HIV Infections in New French Study of On-Demand PrEP"
- POZ, July 2018: "PrEP Use, Compared With HIV Diagnosis Trends, Lags in Youths, Women, the South"
- POZ, July 2018: "PrEP Home Monitoring Kit Works Well in Pilot Study"
- POZ, July 2018: "San Francisco Docs Aren’t Adequately Conducting PrEP Monitoring Tests"
- POZ, July 2018: "Women Likely Shy Away From PrEP Because of Fear of Stigma"
- POZ, June 2018: "Many Health Care Providers Are Willing to Prescribe PrEP to Youths"
- POZ, June 2018: "Young Gay and Bi Men Who Start PrEP Often Soon Stop Using It"
- POZ, June 2018: "Clinicians in South Carolina Are Missing Chances to Prescribe PrEP to High-Risk Patients"
- POZ, June 2018: "Some Gay Men Remain Wary of Condomless Sex With Undetectable HIV-Positive Men"
- POZ, June 2018: "PrEP May Be Accelerating Gay and Bi Men’s Declining Condom Rate"
- POZ, May 2018: "Starting PrEP Is Tied to an Increased Likelihood of Contracting STIs"
- POZ, May 2018: "FDA Approves Truvada as PrEP for Adolescents at Risk for HIV"
- POZ, April 2018: "Long-Acting Antibody Injection Protects Monkeys Against HIV-Like Virus"
- POZ, March 2018: "HIV Rate Among Gay & Bi Men 25 to 34 Rose 45% Between 2008 And 2015"
- POZ, March 2018: "Vaginal Inflammation Lowers Effectiveness of HIV-Preventing Gel"
- POZ, March 2018: "Transmissible HIV That Is Resistant to PrEP Is Rare"
- POZ, March 2018: "A New Case of Apparent PrEP Failure Comes With Hazier Details"
- POZ, March 2018: "AIDSVu Releases State-by-State PrEP-Use Map"
- POZ, March 2018: "Compared With HIV Transmission Trends, PrEP Use Lags Greatly in the South"
- POZ, March 2018: "Remarkably Low Dose of MK-8591 Protects Monkeys Against HIV-Like Virus"
- POZ, March 2018: "CDC Details PrEP’s Woefully Low Use Among Blacks and Latinos"
- POZ, March 2018: "Vaginal Ring Appears to Cut Women’s HIV Rate in Half in New Study"
- POZ, March 2018: "Australian State’s Gay HIV Rate Drops by One Third After PrEP Scale-Up"
- POZ, March 2018: "PrEP’s Effect on Body Fat and Cholesterol Is Minimal"
- POZ, Feb. 2018: "Tweak to Broadly Neutralizing HIV Antibody Makes It Last Longer"
- POZ, Feb. 2018: "As PrEP Use Soars Among Men in California, Racial Disparities Persist"
- POZ, Jan. 2018: "PrEP Isn’t Reaching Those Most at Risk for HIV: Black Gay and Bi Men"
- POZ, Jan. 2018: "PrEP Guidelines Let Young Black Gay and Bi Men Fall Through The Cracks"
- POZ, Dec. 2017: "PrEP Scale-Up Alone Could Take a Bite Out of the HIV Rate"
- POZ, Dec. 2017: "New York City’s HIV Diagnoses Hit a Record Low in 2016"
- POZ, Dec. 2017: "Major Trial of Long-Acting Injectable PrEP Launches Among African Women"
- POZ, Nov. 2017: "San Francisco’s Efforts to Control HIV Are Bearing Impressive Results"
- POZ, Nov. 2017: "In Major PARTNER Study, HIV Rate Is High Outside of Main Relationship"
- POZ, Oct. 2017: "Gay and Bi Men Show Interest in Long-Acting Injectable PrEP"
- POZ, Oct. 2017: "Among Vets on PrEP, Being Older and White Predicts Good Adherence"
- POZ, Oct. 2017: "New York City PrEP Use Increases 10-Fold in Two Years"
- POZ, Oct. 2017: "U.K. HIV Diagnoses Fall 18% in One Year"
- POZ, Oct. 2017: "New Details and Theories Emerge About Third Case of PrEP Failure"
- POZ, Oct. 2017: "CDC: Rising PrEP Use Will Likely Drive Down STIs in Gay & Bi Men"
- POZ, Sept. 2017: "CDC Sees a Record High 2 Million STI Diagnoses in 2016"
- POZ, Sept. 2017: "Scientists Set the Stage for Combination HIV-Antibody Treatment and Prevention"
- POZ, Sept. 2017: "PrEP Is Cost-Effective and May Even Save Money in Many Scenarios"
- POZ, Sept. 2017: "San Francisco Continues to Lead U.S. in Efforts to End HIV Epidemic"
- POZ, Sept. 2017: "Women Must Be More Adherent to PrEP Than Gay and Bi Men"
- POZ, Sept. 2017: "Selzentry as PrEP Is Safe and Well Tolerated Among Women"
- POZ, Aug. 2017: "HIV Diagnoses Continue to Plummet at Major London Sexual Health Clinic"
- POZ, Aug. 2017: "Australian State Sees Record Low HIV Diagnosis Rate"
- POZ, Aug. 2017: "5,000 Cumulative Years of PrEP Use and No HIV Infections"
- POZ, Aug. 2017: "Gonorrhea Diagnoses Fall as PrEP Use Soars at Key London Clinic"
- POZ, Aug. 2017: "An Estimated 136,000 People Are on PrEP in the U.S."
- POZ, Aug. 2017: "Cost and Concerns About Side Effects Keep Gay Men From Taking PrEP"
- POZ, Aug. 2017: "Why Do Gay and Bi Men Prefer On-Demand vs. Daily PrEP?"
- POZ, Aug. 2017: "New Study Validates Research Into Long-Acting PrEP"
- POZ, Aug. 2017: "Taking PrEP After Contracting HIV May Stall a Positive Test Result"
- POZ, Aug. 2017: "Man Who Got HIV Days Before Starting PrEP Spent 7 Months With No Viral Rebound"
- POZ, Aug. 2017: "Men Who Falsely Believe PrEP and Alcohol Don’t Mix Less Likely to Take It"
- POZ, July 2017: "New Evidence That Nondaily Intercourse-Based PrEP Works Well"
- POZ, July 2017: "Vaginal Ring for HIV Prevention Shows Promise in U.S. Adolescents"
- POZ, July 2017: "Gay Men Fold PrEP Into Personal Rules About HIV Risk, Sometimes Easing Them"
- POZ, July 2017: "Yet Another Study Finds No HIV Transmissions When Viral Load Is Undetectable"
- POZ, July 2017: "On PrEP, Young Gay and Bi Men Have More Latex-Free Sex in Long-Term Study"
- POZ, July 2017: "Urine Test Shows Promise as Way to Track Adherence to PrEP"
- POZ, June 2017: "PrEP Greatly Benefits Gay Men’s Sexual-Health and Well-being"
- POZ, June 2017: "Why Are Physicians Reluctant to Prescribe PrEP to Adolescents?"
- POZ, June 2017: "FDA Approves Generic Truvada for HIV Treatment and PrEP"
- POZ, June 2017: "Vaginal Microbiome Differences Likely Lower Anti-HIV Gel’s Efficacy"
- POZ, May 2017: "Taking Birth Control With HIV Treatment or PrEP Is Largely OK"
- POZ, May 2017: "Early PrEP Prescribers Don’t Report Widespread Drop in Condom Use"
- POZ, April 2017: "Researchers Say All Breast-Fed Babies of HIV-Positive Mothers Should Receive PrEP"
- POZ, April 2017: "Dramatic Drop in Gay Londoners’ HIV Diagnoses a Result of TasP and PrEP"
- POZ, March 2017: "Numerous Steps Required for At-Risk Gays to Get on PrEP Limit Its Impact"
- POZ, Feb. 2017: "Seattle Gay and Bi Men on PrEP Have Very High STI Rates."
- POZ, Feb. 2017: "Giving Gay Men on PrEP Antibiotics to Take After Sex Lowers STI Diagnoses."
- POZ, Feb. 2017: "Oral PrEP Works Well in Women With Abnormal Vaginal Microbiota."
- POZ, Feb. 2017: "Vaginal Ring Form of PrEP Does Not Reduce Contraceptive Effectiveness."
- POZ, Feb. 2017: "Long-Acting PrEP May Lead to Drug Resistance if Started During Acute HIV Infection."
- POZ, Feb. 2017: "After Two Decades of Stagnation, U.S. HIV Infection Rate Falls."
- POZ, Feb. 2017: "A Brief Counseling Session Can Boost Adherence to PrEP."
- POZ, Jan. 2017: "HIV Medications, Possibly Including PrEP, May Raise Susceptibility to Syphilis."
- POZ, Jan. 2017: "HIV Diagnoses Plummet at U.K.’s Largest Sexual Health Clinic."
- POZ, Jan. 2017: "STI Diagnoses Rise Among PrEP Users in a Northern California Health System."
- POZ, Dec. 2016: "First Trial of Long-Acting Injectable PrEP Has Begun."
- POZ, Dec. 2016: "What Keeps Men Who Are Willing to Use PrEP From Actually Taking It?"
- POZ, Dec. 2016: "Gay and Bi Men Diagnosed With Syphilis May Be Good PrEP Candidates."
- POZ, Nov. 2016: "Algorithms Can Comb Electronic Medical Records for PrEP Candidates."
- POZ, Nov. 2016: "Researchers Discover Antibody That Thwarts Almost All HIV Strains"
- POZ, Nov. 2016: "HIV Antibody Treatment Has Only Modest Effect"
- POZ, Nov. 2016: "Boston Clinic Sees Steep Rise in STIs Among Men With HIV or on PrEP"
- POZ, Nov. 2016: "Long 'Tail' of Long-Acting HIV Drug Cabotegravir Raises Questions"
- POZ, Nov. 2016: "Those Over 40 Are at Greater Risk of Kidney Function Decline on PrEP"
- POZ, Oct. 2016: "Imagine an Enema That Protects Against HIV"
- POZ, Oct. 2016: "Gay and Bi Men Want Choices With Regard to PrEP"
- POZ, Oct. 2016: "Young Gay and Bi Men Adhere Well to PrEP in Texting Study"
- POZ, Oct. 2016: "Most Women Using Anti-HIV Vaginal Ring Say Sex Felt the Same"
- POZ, Oct. 2016: "Second Man Contracts Rare HIV Strain While Adhering to PrEP"
- POZ, Oct. 2016: "Targeting PrEP to High-Risk Gay Men Is Cost-Effective"
- POZ, Oct. 2016: "Gay and Bi Men’s Overlapping Sexual Partnerships May Fuel HIV’s Spread"
- POZ, Oct. 2016: "Gilead Begins Major Clinical Trial of Descovy vs. Truvada as PrEP"
- POZ, Sept. 2016: "Is Bone Density Loss on PrEP Higher Than Previously Believed?"
- POZ, Sept. 2016: "PrEP Use May Stunt Bone Growth in Young Men."
- POZ, Sept. 2016: "Racial Disparities Seen in PrEP Use Among Young Gay and Bi Men in California."
- POZ, Sept. 2016: "Does PrEP Use Lead to Higher STI Rates Among Gay and Bi Men?"
- POZ, Aug. 2016: "Can We Finally Say That “On-Demand” PrEP Really Does Work?"
- POZ, Aug. 2016: "Women at Risk for HIV Are Often Willing to Take PrEP for Pregnancy."
- POZ, Aug. 2016: "HIV Prevalence Varies Widely Among Gay Men."
- POZ, Aug. 2016: "Zero HIV Transmissions in Major San Francisco PrEP Program."
- POZ, Aug. 2016: "PrEP-Related Bone Loss Is Reversible."
- POZ, Aug. 2016: "The Big News From the 2016 International AIDS Conference."
- POZ, July 2016: "What Determines Higher PrEP Adherence Among Black Gay and Bi Men?"
- POZ, July 2016: "U.S. PrEP Users Likely Exceeded 80,000 by End of 2015."
- POZ, July 2016: "Gay Men’s HIV Rate Low Despite Decline in Condom Use in PrEP Study."
- POZ, July 2016: "Gay and Bi Teens May Need Monthly Monitoring to Adhere Well to PrEP."
- POZ, July 2016: "PrEP and ARVs Vastly Lower Risk of Transmission Between Mixed-HIV Status Straight Couples."
- POZ, July 2016: "High Adherence to Vaginal Ring Reduced HIV Risk Considerably."
- POZ, July 2016: "CDC Warns of Emerging Drug-Resistant Gonorrhea."
- POZ, July 2016: "English Gay Men Report Highly Diverse Sexual Risk Reduction Methods."
- POZ, July 2016: "PrEP Remains a Missed Chance to Curb HIV Among Gay and Bi Men Globally."
- POZ, July 2016: "Keeping Gay Men in Care Is a Major Concern for Long-Term PrEP Use."
- POZ, June 2016: "PrEP Is Popular in San Francisco, but Largely Among White, Older Gay Men."
- POZ, June 2016: "Domestic Violence Is Connected to Lower PrEP Adherence Among Women."
- POZ, June 2016: "How Antiretrovirals Transformed the HIV Epidemic: A Timeline."
- POZ, June 2016: "The HIV Treatment Pipeline."
- POZ, June 2016: "Antiretrovirals: A Success Story. Celebrating 20 Years of Antiretroviral Treatment."
- POZ, June 2016: "Major PrEP Studies Underline Importance of Adherence."
- POZ, June 2016: "PrEP Use Has Soared, but Largely Among White Men Over 25."
- POZ, June 2016: "The Injection Drug Community Is Wary of PrEP."
- POZ, June 2016: "Physicians Are Increasingly Aware of and Willing to Prescribe PrEP."
- POZ, June 2016: "Serosorting, HIV Treatment Do Not Explain Declines in Gay Men’s Condom Use."
- POZ, June 2016: "35 Things You Might Not Know About HIV."
- POZ, May 2016: "Overview of Major PrEP Research Underlines Truvada’s Power to Prevent HIV."
- POZ, May 2016: "The Two Major Factors Indicating That Gay Men Could Benefit From PrEP."
- POZ, April 2016: "Studies Begin to Test Long-Acting Antibody Infusions for HIV Prevention."
- POZ, April 2016: "Single Antibody Shot Provides Long-Term HIV Protection in Monkeys."
- POZ, April 2016: "Targeting Injection Drug Users With PrEP Is Not the Best Use of Funds."
- POZ, April 2016: "Test and Treat, Plus PrEP Could Slash New HIV Cases."
- POZ, April 2016: "FDA OKs Gilead’s Descovy, a Safer Version of Truvada, for HIV Treatment Only (Not for PrEP)."
- POZ, March 2016: "Women Need to Adhere Better to PrEP Than Men to Be Protected Against HIV."
- POZ, March 2016: "Injectable Long-Acting Isentress as PrEP Protects Mice Against Vaginal HIV Exposure."
- POZ, March 2016: "PrEP’s Arrival in SF Coincided With Accelerated Rise in Sexual Risk Taking in Gay/Bi Men."
- POZ, March 2016: "PrEP Awareness and Use is Rising in Gay Men, But Major Uptake is Limited to a Few Cities."
- POZ, March 2016: "PrEP is On The Rise in NYC Gay Men, With Higher-Risk Guys More Inclined Toward Its Use."
- POZ, March 2016: "1 in 6 Men in Intercourse-Based PrEP Study Had Low Truvada and Condom Use."
- POZ, March 2016: "CROI Roundup: All the HIV News That’s Fit to Print."
- POZ, March 2016: "Monkey Study: TAF-Based Truvada Works as PrEP, But Early Human Study Raises Doubts."
- POZ, Feb. 2016: "Viread (Tenofovir, or TDF) Use, Raises Bone Fracture Risk in People With HIV."
- POZ, Feb. 2016: "Gay Men and Trans Women Adhere Well to Rectal Gel As PrEP in Early Study."
- POZ, Feb. 2016: "Tailored Intervention Succeeds in Getting Black Gay Men Interested In, Adhering to PrEP."
- POZ, Feb. 2016: "Injectable Long-Acting Cabotegravir Shows Promise As PrEP in Early Safety Trial."
- POZ, Feb. 2016: "Expanding HIV Testing, Treatment and PrEP Could Slash New HIV Cases by 70% by 2020."
- POZ, Feb. 2016: "Selzentry (Maraviroc) Shows Promise as an Alternative to Truvada as PrEP."
- POZ, Feb. 2016: "CDC’s STI Testing Guidelines For People on PrEP Are Too Lax."
- POZ, Feb. 2016: "Truvada as PrEP Against HIV Leads to Modest Decline in Kidney Function."
- POZ, Feb. 2016: "Among Young Adults, Bone Density Loss From PrEP Reverses After Stopping Truvada."
- POZ, Feb. 2016: "Similarly Modest HIV-Prevention Benefit of Vaginal Ring Seen in Early Results of Second Study."
- POZ, Feb. 2016: "Vaginal Ring For HIV Prevention Yields Modest Overall Benefit, Works Better in Older Women."
- POZ, Jan. 2016: "Tenofovir Resistance Is Common in Those Failing HIV Meds."
- POZ, Jan. 2016: "Gilead Seeks Approval of Truvada as PrEP in Europe."
- POZ. Jan. 2016: "Tenofovir Alone as PrEP May Fail."
- POZ, Jan. 2016: "PrEP Could Halve HIV Rate in British Gay Men."
- POZ, Jan. 2016: "Viread (Tenofovir, TDF) Linked With Liver Disease and Cancer."
- POZ, Jan. 2016: "Short- or Medium-Term PrEP Is Safer Than Aspirin."
- POZ, Dec. 2015: "Non-Daily PrEP Study Raises Doubts of Its Real-World Applicability"
- POZ, Nov. 2015: "CDC Says 1.2 Million Americans Are Likely Candidates for PrEP"
- POZ, Nov. 2015: "Mon Dieu, France Approves PrEP!"
- POZ, Nov. 2015: "Very Low HIV Rate in Study of High-Risk Gays on PrEP."
- POZ, Nov. 2015: "‘PrEP Works if You Take It’ for Trans Women Too."
- POZ, Oct. 2015: "Does Truvada as PrEP Stunt Bone Growth in Young Men?"
- POZ, Oct. 2015: "More Infectious Disease Docs Are Prescribing PrEP."
- POZ, Sept. 2015: "WHO Calls For HIV Treatment For All, Supports Broader PrEP Use."
- POZ, Sept. 2015: "Preventing HIV With Limited Funds? Choose Treatment Over PrEP."
- POZ, Sept. 2015: "PROUD Study Results ‘Strongly Support’ UK PrEP Use in New Paper."
- POZ, Sept. 2015: "Gays Are Talking About PrEP and Viral Load on Social Apps."
- POZ, Sept. 2015: "PrEP 'Care Continuum' IDs Barriers to Effective HIV Prevention."
- POZ, Aug. 2015: “AIDS Healthcare Foundation Cedes Ground in Anti-PrEP Fight.”
- POZ, Aug. 2015: “Gilead Applies for PrEP Approval in Canada.”
- POZ, Aug 2015: “Highest-Risk Gay and Bi Men Likeliest to Join Brazilian PrEP Study.”
- POZ, Aug 2015: “PrEP Is Safe for People With Hepatitis B.”
- POZ, July 2015: “Some PrEP Success Among White and Latino Gay Youth.”
- POZ, July 2015: “Non-Daily PrEP Likely Works For Anal, Not Necessarily Vaginal, Sex.”
- POZ, July 2015: “Intercourse-Based PrEP Yields Lower Adherence Than Daily Dosing.”
- POZ, July 2015: “Excellent Adherence, No New HIV Cases in Heterosexual PrEP Trial.”
- POZ, July 2015: “Gay and Bi Men Adhere Well to PrEP in U.S. Real-World Study.”
- POZ, July 2015: “Prioritizing PrEP for High-Risk Kenyans Likely Spells Success.”
- POZ, July 2015: “AHF Refuses to Correct Misleading Anti-PrEP Ad.”
- POZ, June 2015: “AIDS Healthcare Foundation Issues Latest Anti-PrEP Salvo.”
- POZ, May 2015: “PrEP Reaches Top Effectiveness After a Week of Daily Dosing.”
- POZ, May 2015: “PrEP Prescriptions on Dramatic Upswing in New York State.”
- POZ, May 2015: “PrEP-Delivering Subdermal Implant Shows Promise in Animal Study.”
- POZ, April 2015: “Truvada as PrEP Leads to Small Initial Decrease in Bone Density.”
- POZ, April 2015: “Gay and Bi Men Eager to Enter PrEP Demonstration Project.”
- POZ, April 2015: “Women in Failed PrEP Trial Lied About Pill Use to Stay In Study.”
- POZ, April 2015: “Poll of HIV Providers Finds Some Reluctance Toward PrEP Prescribing.”
- POZ, April 2015: “No Matter How You Slice It, PrEP Rollout Should Save Money.”
- POZ, March 2015: “Single Dose of Selzentry Does Not Reach Levels High Enough for PrEP.”
- POZ, March 2015: “As PrEP Use in San Francisco Rises, Hope for Cutting HIV Rates.”
- POZ, Feb. 2015: “Daily PrEP + ARVs in Mixed-HIV Status Couples = Prevention Success.”
- POZ, Feb. 2015: “PrEP Reduces Group of Gay Men’s Risk of HIV By 86% in UK PROUD Study.”
- POZ, Feb. 2015: “Intercourse-Based PrEP Dosing Lowers HIV Risk in Gays, But Why?”
- POZ, Feb. 2015: “PrEP Users’ Sexually Acquired Hep C Suggests Need for Routine Testing.”
- POZ, Feb. 2015: “Daily Antibiotic May Work as PrEP Against STIs Other Than HIV.”
- POZ, Feb. 2015: “Failed VOICE PrEP Trial Failed to Preempt Lies About Adherence.”
- POZ, Jan. 2015: “Primate Studies Raise Hope of Eventual Quarterly Injected PrEP.”
- POZ, Jan. 2015: “While Rare, Drug Resistance After Contracting HIV on PrEP Can Occur.
- POZ, Jan. 2015: “Gay Men’s Ability to Predict Having Sex Has Implications for PrEP Dosing.”
- POZ, Dec. 2014: “Pushing PrEP in HIV 'Hot Zones' Better Combats the Virus.”
- POZ, Dec. 2014: “45% of PrEP Users at SF Clinic Report Using Condoms Less Often.”
- POZ, Dec. 2014: “Conceiving a Child on Truvada as PrEP Appears Safe.”
- POZ, Nov. 2014: “Latest Data on PrEP, Though Patchy, Indicates Rising Use Among Men.”
- POZ, Nov. 2014: “More PrEP Needed To Prevent HIV Via Vaginal Than Anal Sex.”
- POZ, Oct. 2014: “High Efficacy Halts Placebo Phase of Intermittent PrEP Study.”
- POZ, Oct. 2014: “Calculating PrEP’s Capacity to Prevent HIV in the Real World.”
- POZ, Oct. 2014: “High Efficacy for PrEP Among Gay Men in English Study.”
- POZ, Sept. 2014: “Americans Adhered Well to PrEP in Global iPrEx Study.”
- POZ, Sept. 2014: “Targeting PrEP to High-Risk Gays Would Lower HIV—For a Huge Price.”
- POZ, Sept. 2014: “New HIV Antibody Target Could Aid a Vaccine, Treatment or PrEP.”
- POZ, Aug. 2014: “Gays’ Desire for Intimacy With Main Partner Is Linked to PrEP Interest.”
- POZ, Aug. 2014: “Vancouver Injection Drug Users Moderately Interested in PrEP.”
- POZ, July 2014: “European Health Agency Wants More Answers About PrEP.”
- POZ, July 2014: “Study on Intermittent Dosing of PrEP Suggests High Adherence.”
- POZ, July 2014: “Expert Panel’s Advice for HIV Prevention Includes PrEP.”
- POZ, July 2014: “PrEP May Be Safe for Women Seeking to Get Pregnant.”
- POZ, July 2014: “WHO Supports PrEP, Media Bungles The Story With Hyperbole.”
- POZ, July 2014: “PrEP May Reduce Risk of Herpes By a Third.”
- POZ, July 2014: “Gay Men at Risk May Not See Themselves as PrEP Candidates.”
- POZ, June 2014: “Clinicians Can Raise PrEP Uptake Among Gay and Bisexual Men.”
- POZ, June 2014: “Early PrEP Users Report Reduced Anxiety About HIV Risk.”
- POZ, June 2014: “Strong Link Between Taking PrEP Daily and Preventing HIV.”
- POZ, May 2014: “Preliminary Estimate Says PrEP Takes 7 Days to Work.”
- POZ, May 2014: “Seroconverting on PrEP Not a Major Risk For Truvada Resistance.”
- POZ, May 2014: “CDC Issues New Guidelines for Using Truvada as PrEP.”
- POZ, March 2014: “PrEP Adherence Varies Greatly Between Cities.”
- POZ, March 2014: “Man, Briefly on PrEP, Who Began HIV Treatment 5 Days In Appears Virus-Free”
- POZ, March 2014: “Early Trial Raises Hopes of Quarterly PrEP Injections.”
- POZ, March 2014: “Monthly PrEP Injections Show Promise in Female Monkeys.”
- POZ, Feb. 2014: “A Likely Uptick in PrEP Users as Studies Seek New Answers.”
- POZ, Jan. 2014: “Another Study Suggests PrEP Doesn’t Lead to Riskier Sex.”
- POZ, Dec. 2013: “ID Docs Widely Support PrEP, Yet Only 9% Write Scripts.”
- POZ, Oct. 2013: “Unaware They’re at Risk, Gay Men Less Likely to Use PrEP.”
- POZ, Sept. 2013: “PrEP Adherence Curbs HIV Transmission in Straight Couples.”
- POZ, Sept. 2013: “PrEP Did Not Increase Sexual Risks in Study of Gay Men.”
- POZ, June 2013: “Trial of PrEP in Drug Users Called Into Question.”
- POZ, April 2013: “Study Suggests PrEP May Not Increase Overall Sexual Risk-Taking in Gay Men.”
- POZ, March 2013: “Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission.”
- POZ, March 2013: “Young Gay Men’s PrEP Study Shows Feasibility and Challenges.”
- POZ, March 2013: “Women's PrEP Trial Interventions Fail to Protect From HIV.”